Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate
The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
1 . A method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir.
2 . The method of claim 1 wherein the disease or disorder is unconjugated hyperbilirubinemia.
3 . The method of claim 1 wherein the UGT1A1 substrate is bilirubin.
4 . The method of claim 1 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily.
5 . A method for treating unconjugated hyperbilirubinemia comprising the step of administering an effective amount of ritonavir to a subject in need thereof.
6 . The method of claim 5 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily.
7 . A method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate upon administration of an active pharmaceutical ingredient comprising the step of co-administering ritonavir in an effective amount to a subject in need thereof.
8 . The method of claim 7 wherein the effective amount of ritonavir is in a range of about 25 mg to about 1200 mg.
9 . The method of claim 7 wherein the active pharmaceutical ingredient is selected from the group consisting essentially of indinavir, atazanavir, amphotericin B/cholesteryl sulfate complex, testosterone, interferon beta-1b, bicalutamide, ciprofloxacin, oxaliplatin, floxuridine, gemcitabine hydrochloride, sargramostim, gemtuzumab ozogamicin, vinorelbine tartrate, carboplatin, peginterferon alfa-2B, tacrolimus, aldesleukin, dalfopristin/quinupristin, didanosine and capecitabine.
10 . The method of claim 7 wherein the active pharmaceutical ingredient is indinavir.
11 . The method of claim 7 wherein the active pharmaceutical ingredient is atazanavir.
12 . The method of claim 7 wherein the disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate is unconjugated hyperbilirubinemia.
13 . A method for increasing glucuronidation of an UGT1A1 substrate comprising the step of administering an effective amount of ritonavir.
14 . The method of claim 13 wherein the UGT1A1 substrate is bilirubin.
15 . The method of claim 13 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily.
16 . A method for increasing excretion of an UGT1A1 substrate comprising the step of administering an effective amount of ritonavir.
17 . The method of claim 16 wherein the UGT1A1 substrate is bilirubin.
18 . The method of claim 16 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily.